DLDixian Luo

Dixian Luo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dixian Luo has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Yao Shen

    Laboratory Medicine Center, Shenzhen Luohu Hospital Group, The Third Affiliated Hospital, The Affiliated Luohu Hospital) of Shenzhen University, Shenzhen, P. R. China

    3 shared publications
  • Ailin Qiu

    Laboratory Medicine Center, Shenzhen Luohu Hospital Group, The Third Affiliated Hospital, The Affiliated Luohu Hospital) of Shenzhen University, Shenzhen, P. R. China

    2 shared publications
  • Dennis K. P. Ng

    Department of Chemistry The Chinese University of Hong Kong Hong Kong China

    2 shared publications
  • Evelyn Y. Xue

    Department of Chemistry The Chinese University of Hong Kong Shatin, N.T. Hong Kong 999077 China

    2 shared publications
  • Gun Yang

    Department of Laboratory Medicine Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital) Shenzhen University Shenzhen 518052 China

    2 shared publications
  • Qingshuang Zou

    Department of Chemistry The Chinese University of Hong Kong Shatin, N.T. Hong Kong 999077 China

    2 shared publications

Latest Publications

  • Open Access

    AKR1B10 mediates glycolysis and proliferation in breast cancer via the IGF2R-PGK1-H4K12la-mTOR signaling axis

    by Shang Chen, Ailin Qiu, Qian Hu, Quan Liu, Yaming Zhang, Xiaosha Wen, Li Wang, Yan He, Yao Shen, Deliang Cao, et al.

  • Open Access

    Discovery and screening of thermostable signature peptides for robust quantification of wheat allergens in processed foods

    by Yingjun Lu, Xiaojing Yu, He Li, Jingwen Sun, Yan Chen, Xiaomei Zhang, Xiaosha Wen, Dixian Luo, Hua Ji, Hongwei Zhang


  • Open Access

    A novel four-serum marker model for early detection and therapeutic monitoring of breast cancer

    by Shang Chen, Jianling Zeng, Ke Gong, Yaru Liu, Shoubin Long, Li Han, Dixian Luo

    Early diagnosis of breast cancer (BC) remains pivotal for enhancing patient outcomes, yet current imaging modalities face inherent limitations. This retrospective study, encompassing 1366 BC patients and 1186 healthy controls (HC) from Shenzhen Nanshan People’s Hospital (2022–2025), developed and validated a serum tumor marker-based predictive model to address this gap. Eight markers—CEA, AFP, CA199, CA242, CA15-3, CA125, FER, and NSE—were analyzed, with multivariate logistic regression identifying AFP, CA242, CA15-3, and NSE as independent diagnostic predictors. The resulting four-marker panel demonstrated robust performance, achieving an AUC of 0.90 (95% CI: 0.89–0.92) with 77.3% sensitivity and 89.7% specificity in the development cohort (n = 1535), and sustained efficacy in validation (AUC = 0.82, 87.5% sensitivity, 72.8% specificity; n = 761). The model effectively stratified early-stage (T1/T2: 86.49% accuracy) versus advanced-stage (T3/T4: 92.00%) tumors, lymph node involvement (N0: 86.49%; N+: 88.00%), metastatic status (M0: 87.32%; M+: 85.71%), and molecular subtypes (Luminal A: 91.33%; Luminal B: 82.35%; HER2+: 84.61%; triple-negative: 87.75%). Notably, longitudinal risk score trends correlated with therapeutic response, declining in remission and rising with progression. These findings collectively highlight the model’s dual utility as a high-accuracy diagnostic tool for early BC detection and a dynamic biomarker for monitoring treatment efficacy. This novel model may provide an auxiliary approach in current screening paradigms, underscoring its transformative potential in oncology practice.


  • Open Access

    Fabrication of Polydopamine‐Coated High‐Entropy MXene Nanosheets for Targeted Photothermal Anticancer Therapy

    by Qingshuang Zou, Ailin Qiu, Yan He, Evelyn Y. Xue, Lujie Wang, Gun Yang, Yao Shen, Dixian Luo, Quan Liu, Dennis K. P. Ng

    Transition metal carbides, nitrides, and carbonitrides (MXenes) have emerged as a promising class of 2D materials that can be used for various applications. Recently, a new form of high‐entropy MXenes has been reported, which contains an increased number of elemental species that can increase the configurational entropy and reduce the Gibbs free energy. The unique structure and composition lead to a range of intriguing and tunable characteristics. Herein, the fabrication of high‐entropy MXene TiVNbMoC3Tx (T = surface terminations) with a layer of polydopamine is reported, followed by immobilization of a phthalocyanine‐based fluorophore for imaging and the peptide sequence QRHKPREGGGSC for targeting the epidermal growth factor receptor (EGFR) overexpressed in cancer cells. The resulting nanocomposite exhibits high biocompatibility and superior photothermal property. Upon laser irradiation at 808 nm, the light‐to‐heat conversion efficiency is up to 56.1%, which is significantly higher than that of conventional 2D materials. In vitro studies show that these nanosheets could be internalized selectively into EGFR‐positive cancer cells and effectively eliminate these cells mainly through photothermal‐induced apoptosis. Using 4T1 tumor‐bearing mice as an animal model, the nanosheets could accumulate at the tumor and effectively eradicate the tumor upon laser irradiation without causing noticeable adverse effects to the mice.


  • Open Access

    Photo‐metallo‐immunotherapy: Fabricating Chromium‐Based Nanocomposites to Enhance CAR‐T Cell Infiltration and Cytotoxicity against Solid Tumors

    by Qingshuang Zou, Ke Liao, Guangchao Li, Xin Huang, Yongwei Zheng, Gun Yang, Min Luo, Evelyn Y. Xue, Chuanqing Lan, Shuai Wang, et al.

    The infiltration and cytotoxicity of chimeric antigen receptor (CAR)‐T cells are crucial for effective elimination of solid tumors. While metallo‐immunotherapy is a promising strategy that can activate the antitumor immunity, its role in promoting CAR‐T cell therapy remains elusive. The first single‐element nanomaterial based on chromium nanoparticles (Cr NPs) for cancer photo‐metallo‐immunotherapy has been reported previously. Herein, an extended study using biodegradable polydopamine as a versatile carrier for these nanoparticles, enabling synergistic CAR‐T cell therapy, is reported. The results show that these nanocomposites with or without further encapsulation of the anticancer drug alpelisib can promote the CAR‐T cell migration and antitumor effect. Upon irradiation with near‐infrared light, they caused mild hyperthermia that can “warm” the “cold” tumor microenvironment (TME). The administration of B7‐H3 CAR‐T cells to NOD severe combined immunodeficiency gamma mice bearing a human hepatoma or PIK3CA‐mutated breast tumor can significantly inhibit the tumor growth after the induction of tumor hyperthermia by the nanocomposites and promote the secretion of serum cytokines, including IL‐2, IFN‐γ, and TNF‐α. The trivalent Cr3+ ions, which are the major degradation product of these nanocomposites, can increase the CXCL13 and CCL3 chemokine expressions to generate tertiary lymphoid structures (TLSs) in the tumor tissues, facilitating the CAR‐T cell infiltration.